Eli Lilly and Takeda End Agreement to Co-Develop Ruboxistaurin Mesylate

Ruboxistaurin mesylate is used to treat diabetic macular edema and diabetic peripheral neuropathy. The companies said that after looking at the overall results, the trials did not meet the criteria for Phase III studies and therefore they have agreed to terminate the contract.

This agent is an investigational compound discovered and developed by Eli Lilly. In Japan, pursuant to an agreement concluded on December 18, 2003, phase 2 clinical studies for the treatment of diabetic peripheral neuropathy and diabetic macular edema have been conducted by Eli Lilly Japan and Takeda respectively.

Eli Lilly and Takeda judged that the overall results of diabetic peripheral neuropathy and diabetic macular edema clinical studies did not meet its pre-specified go/no go decision criteria for phase 3 clinical studies, and agreed to terminate the original agreement.

===========================

Learn about the ONlY Instant Disposable In Office A1c Test:  Studies have shown that by providing the A1c test in the office while the patient is present, can lower A1c by a full point.  Learn about the only 99% accurate disposable A1c test that is CLIA waived and cost less then 10 dollars and reimbursed at least 21 dollars.     https://www.a1ctest.com

===========================

Help us keep this newsletter free—update your profile!!!!!!!!!!!!!!!!!!!!!!
https://www.diabetesincontrol.com/surveys/index.php